Terms: = Pancreatic cancer AND SRC, c-SRC, 6714, ENSG00000197122, P12931, ASV, p60-Src, SRC1, c-src AND Treatment
133 results:
1. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
2. Radiation-Activated Cobalamin-Kinase Inhibitors for treatment of pancreatic Ductal Adenocarcinoma.
Gendron LN; Sheveland CG; Gunn JR; Pogue BW; Shell TA; Shell JR
Mol Pharm; 2024 Jan; 21(1):137-142. PubMed ID: 37989273
[TBL] [Abstract] [Full Text] [Related]
3. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the treatment of KRAS Mutant cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract] [Full Text] [Related]
4. src is a target molecule of mannose against pancreatic cancer cells growth in vitro & in vivo.
Xie J; Wu S; Liao W; Ning J; Ding K
Glycobiology; 2023 Oct; 33(10):766-783. PubMed ID: 37658770
[TBL] [Abstract] [Full Text] [Related]
5. EGFR-Induced and c-src-Mediated CD47 Phosphorylation Inhibits TRIM21-Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion.
Du L; Su Z; Wang S; Meng Y; Xiao F; Xu D; Li X; Qian X; Lee SB; Lee JH; Lu Z; Lyu J
Adv Sci (Weinh); 2023 Sep; 10(27):e2206380. PubMed ID: 37541303
[TBL] [Abstract] [Full Text] [Related]
6. Network pharmacology-based anti-pancreatic cancer potential of kaempferol and catechin of Trema orientalis L. through computational approach.
Agrawal S; Das R; Singh AK; Kumar P; Shukla PK; Bhattacharya I; Tripathi AK; Mishra SK; Tiwari KN
Med Oncol; 2023 Apr; 40(5):133. PubMed ID: 37010624
[TBL] [Abstract] [Full Text] [Related]
7. Targeting src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models.
Su L; Chen Y; Huang C; Wu S; Wang X; Zhao X; Xu Q; Sun R; Kong X; Jiang X; Qiu X; Huang X; Wang M; Wong PP
Sci Transl Med; 2023 Jan; 15(678):eabl7895. PubMed ID: 36630483
[TBL] [Abstract] [Full Text] [Related]
8. Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for pancreatic cancer.
Chen H; Zhou W; Bian A; Zhang Q; Miao Y; Yin X; Ye J; Xu S; Ti C; Sun Z; Zheng J; Chen Y; Liu M; Yi Z
Clin Cancer Res; 2023 Feb; 29(4):815-830. PubMed ID: 36374556
[TBL] [Abstract] [Full Text] [Related]
9. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant pancreatic cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract] [Full Text] [Related]
10. Small molecule inhibitor against onco-mucins disrupts src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma.
Zhang C; Atri P; Nallasamy P; Parte S; Rauth S; Nimmakayala RK; Marimuthu S; Chirravuri-Venkata R; Bhatia R; Halder S; Shah A; Cox JL; Smith L; Kumar S; Foster JM; Kukreja RC; Seshacharyulu P; Ponnusamy MP; Batra SK
Cancer Lett; 2022 Dec; 551():215922. PubMed ID: 36285687
[TBL] [Abstract] [Full Text] [Related]
11. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
12. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer.
Bose M; Sanders A; De C; Zhou R; Lala P; Shwartz S; Mitra B; Brouwer C; Mukherjee P
Transl Res; 2023 Mar; 253():41-56. PubMed ID: 36031050
[TBL] [Abstract] [Full Text] [Related]
13. Opposite Effects of src Family Kinases on YAP and ERK Activation in pancreatic cancer Cells: Implications for Targeted Therapy.
Sinnett-Smith J; Anwar T; Reed EF; Teper Y; Eibl G; Rozengurt E
Mol Cancer Ther; 2022 Nov; 21(11):1652-1662. PubMed ID: 35999654
[TBL] [Abstract] [Full Text] [Related]
14. A Rare Case of Synchronous Intraductal Papillary Mucinous Neoplasm-Associated pancreatic Adenocarcinoma and Signet Ring Cell Gastric Adenocarcinoma.
Shupp B; Liaquat H; Rollins S; Stoll L; Singh G; Quiros RM; Matin A
Am J Case Rep; 2022 Aug; 23():e935242. PubMed ID: 35939415
[TBL] [Abstract] [Full Text] [Related]
15. Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
Yang Y; Akashi Y; Shimomura O; Tateno H; Saito S; Hiemori K; Miyazaki Y; Furuta T; Kitaguchi D; Kuroda Y; Pakavarin L; Oda T
Gastric Cancer; 2022 Sep; 25(5):896-905. PubMed ID: 35715659
[TBL] [Abstract] [Full Text] [Related]
16. Potential therapeutic effects of hAMSCs secretome on Panc1 pancreatic cancer cells through downregulation of SgK269, E-cadherin, vimentin, and snail expression.
Alidoust Saharkhiz Lahiji M; Safari F
Biologicals; 2022 Apr; 76():24-30. PubMed ID: 35216916
[TBL] [Abstract] [Full Text] [Related]
17. The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 signaling.
Safari F; Shafiee Nejad N; Aghaei Nejad A
Med Oncol; 2022 Jan; 39(3):28. PubMed ID: 35059869
[TBL] [Abstract] [Full Text] [Related]
18. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Yu HY; Lee CY; Lin LG; Chao Y; Li CP
J Chin Med Assoc; 2022 Jan; 85(1):42-50. PubMed ID: 34759212
[TBL] [Abstract] [Full Text] [Related]
19. Disulfiram Synergizes with src Inhibitors to Suppress the Growth of pancreatic Ductal Adenocarcinoma Cells in Vitro and in Vivo.
Li Z; Xie X; Tan G; Xie F; Liu N; Li W; Sun X
Biol Pharm Bull; 2021; 44(9):1323-1331. PubMed ID: 34471060
[TBL] [Abstract] [Full Text] [Related]
20. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation.
Guo Y; Xiao Y; Guo H; Zhu H; Chen D; Wang J; Deng J; Lan J; Liu X; Zhang Q; Bai Y
Aging (Albany NY); 2021 Jul; 13(14):18545-18563. PubMed ID: 34320467
[TBL] [Abstract] [Full Text] [Related]
[Next]
